Paradigm Therapeutics raises $12.5 million from Eshelman Ventures to support the development of SD-101, a topical therapy for Epidermolysis Bullosa, and plans for NDA submission in 2025.
Paradigm Therapeutics raises $12.5 million from Eshelman Ventures to support the development of SD-101, a topical therapy for Epidermolysis Bullosa, and plans for NDA submission in 2025.
05/06/25, 3:42 PM
Location
mount pleasantMoney raised
$12.5 million
Industry
therapeutics
pharmaceutical
biotechnology
health care
Investors
Eshelman Ventures, Llc
Paradigm Therapeutics, Inc. has announced a $12.5 million investment by Eshelman Ventures, LLC. This funding will support the completion of development activities for SD-101 (Zorblisa™) and an NDA submission in late 2025. Dr
Company Info
Location
mount pleasant, south carolina, united states
Additional Info
Paradigm Therapeutics, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. Paradigm's main focus is the treatment of Epidermolysis Bullosa (EB). SD-101 (Zorblisa™), its leading therapy for the treatment of skin effects in patients with Epidermolysis Bullosa, has completed Phase II and Phase III clinical trials. SD-101 (Zorblisa™) is a topical cream that requires no special handling and can be stored at room temperature and has demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes.